29 January 2026

Innovative Molecules Announces Completion of Phase 1 Program and Advancement to Phase 2 for Oral Adibelivir

Read More +
13 January 2026

Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease

Read More +
03 September 2025

Publication in Antiviral Research: Structural determinants of nervous system exposure of adibelivir (IM-250) and related herpes helicase-primase inhibitors across animal species

Read More +
27 October 2023

Publication in Antiviral Research: Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV

Read More +
15 June 2023

Innovative Molecules Announces First Subjects Dosed in the German Phase 1 Clinical Trial of IM-250

Read More +
16 June 2021

Science Translational Medicine Publication: Innovative Molecules ́ Drug Candidate Affects Recurrent Herpes Simplex Virus Infections

Read More +
07 June 2021

Innovative Molecules raises €20 million Series A equity financing round

Read More +